TransCode Therapeutics, Inc. announced that Daniel Vlock, M.D., has been appointed as the company?s Chief Medical Officer. Dr. Vlock is a medical oncologist with over 25 years of industry experience and 15 years in academia, including renowned institutions Yale University, University of Pittsburgh, and Harvard University. Dr. Vlock has successfully supported start-up, emerging, and established companies with diverse product portfolios.

He has played key roles in managing pre-IND, phase I, II and III clinical trials, and post?approval studies for more than 40 oncology development programs. While at Pharmacia, Dr. Vlock ran the Celebrex Oncology program involving two pivotal clinical trials and over 3,500 patients. His team was responsible for European approval of Celebrex for the treatment of familial adenomatous polyposis. As CEO of Alopexx, Inc., Dr. Vlock was responsible for the development of drugs in oncology, infectious diseases, Alzheimer?s Disease and muscular dystrophy.

His expertise spans important aspects of oncology development, including clinical trial design and strategy, interactions with regulatory agencies, and medical oversight of clinical trials. Dr. Vlock obtained his M.D. from Baylor College of Medicine. He completed his residency training in Internal Medicine at Temple University Hospital and a fellowship in Medical Oncology at Yale University School of Medicine.

Dr. Vlock initially will serve on a part-time basis through TransCode?s arrangement with BioBridges LLC.